This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Congenica, a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale, has announced a two-year extension to its contract for the Hong Kong GenomeProject (HKGP), the first large-scale genome sequencing initiative in Hong Kong.
The pilot phase of the project will focus on the drug allopurinol, which is used to treat gout by lowering uric acid in your blood and is marketed by several companies including Aspen Pharmacare as Zyloric in the UK. In December 2018, the 100,000 GenomesProject reached its goal of sequencing 100,000 whole genomes.
Rather than be provided a therapy that has been tested across a broad range of the population, there are now many therapies on the market that are designed specifically to work for sub-populations within disease areas. The information gathered from the project is still providing insights today, a decade later.
Thanks to the dedicated efforts of doctors, patients, carers, and healthcare professionals, people diagnosed with blood cancer are now living longer, with a steady stream of more effective treatments entering the market each year. 2012 – The 100,000 GenomicsProject begins. 2016–2022 — New treatments enter the market.
From the Human GenomeProject to contemporary drug development, collaboration is critical to the life sciences. While Charleston has a lot to offer life sciences businesses, the connectivity of the mid-sized market is one of the things making the location so special.
Collecting data on orphan drugs : Collecting data related to rare diseases and orphan drugs already existing in the market is a time and cost-intensive process. For instance, the UK government’s 100K GenomesProject has achieved its goal of sequencing the genomes of 100,000 people in 2019.
Likely Growth of the Spatial Omics Solutions Market. During our research, we estimated the market under conservative, base and optimistic scenarios. As per the base case forecast scenario, market for spatial omics solutions is estimated to be worth over USD XX billion, growing at an annualized rate of XX%, in the given time period.
A key element of this partnership involves Lifebit’s CloudOS platform – a powerful, secure and cutting-edge platform used by a growing number of research organizations and governments globally, such as Genomics England and The Hong Kong GenomeProject. Source link: [link].
and European Union (EU) approvals, will also be presented, including long-term outcomes in patients with TRK fusion cancer receiving larotrectinib and data from the 100,000 GenomesProject analyzing the prognostic factor for survival for patients with tumors that harbor a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion.
“However, around the time of the Human GenomeProject, there was a ‘land grab’ for the new technologies as big pharmaceuticals tried to catch up paying high prices to access technology platforms in areas such as genomics and high throughput screening.”
Nutrigenomics is the science studying the relationship between human genome, nutrition and health. In part, the success of the Human GenomeProject has also paved a path for the novel concept of nutrigenomics. Nutrigenomics testing is one of the first applications of the human genomeproject which was made public.
As a result, the advancement in genetic sequencing, powered by programs such as The Cancer Genome Atlas and the 100,000 GenomesProject, has led to a greater understanding of the genes that have direct implications in the causes of cancer.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content